These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 6388070

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.
    Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, LaQuaglia MP, Tolkoff-Rubin N, Rubin RH, Herrin JT, Russell PS.
    Transplantation; 1981 Dec; 32(6):535-9. PubMed ID: 7041358
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of the immunosuppressive effect of fractionated total lymphoid irradiation (TLI) vs conventional immunosuppression (CI) in renal cadaveric allotransplantation.
    Waer M, Vanrenterghem Y, Ang KK, Van der Schueren E, Michielsen P, Vandeputte M.
    J Immunol; 1984 Feb; 132(2):1041-8. PubMed ID: 6228588
    [Abstract] [Full Text] [Related]

  • 8. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
    Waid TH, Lucas BA, Amlot P, Janossy G, Yacoub M, Cammisuli S, Jezek D, Rhoades J, Brown S, Thompson JS.
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
    [Abstract] [Full Text] [Related]

  • 9. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent.
    Vigeral P, Chkoff N, Chatenoud L, Campos H, Lacombe M, Droz D, Goldstein G, Bach JF, Kreis H.
    Transplantation; 1986 Jun; 41(6):730-3. PubMed ID: 3520988
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Use of OKT3 monoclonal antibody in the treatment of acute cardiac allograft rejection.
    Klein JB, McLeish KR, Bunke CM, Chang B, Ganzel BL, Slater AD, Gray LA.
    Transplantation; 1988 Apr; 45(4):727-9. PubMed ID: 3282354
    [Abstract] [Full Text] [Related]

  • 12. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression.
    Jaffers GJ, Fuller TC, Cosimi AB, Russell PS, Winn HJ, Colvin RB.
    Transplantation; 1986 May; 41(5):572-8. PubMed ID: 3085297
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B, Light S, Hardie IR, Lin A, Johnson JR.
    Transplantation; 1999 Jan 15; 67(1):110-5. PubMed ID: 9921806
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.